Kamath Atul F, McGraw Michael H, Israelite Craig L
Atul F Kamath, Michael H McGraw, Craig L Israelite, Department of Orthopedic Surgery, the Center for Hip Preservation, Penn Medicine, University of Pennsylvania, Philadelphia, PA 19107, United States.
World J Orthop. 2015 Nov 18;6(10):776-82. doi: 10.5312/wjo.v6.i10.776.
Sickle cell disease is a known risk factor for osteonecrosis of the hip. Necrosis within the femoral head may cause severe pain, functional limitations, and compromise quality of life in this patient population. Early stages of avascular necrosis of the hip may be managed surgically with core decompression with or without autologous bone grafting. Total hip arthroplasty is the mainstay of treatment of advanced stages of the disease in patients who have intractable pain and are medically fit to undergo the procedure. The management of hip pathology in sickle cell disease presents numerous medical and surgical challenges, and the careful perioperative management of patients is mandatory. Although there is an increased risk of medical and surgical complications in patients with sickle cell disease, total hip arthroplasty can provide substantial relief of pain and improvement of function in the appropriately selected patient.
镰状细胞病是已知的髋部骨坏死风险因素。股骨头内的坏死可能导致该患者群体出现严重疼痛、功能受限并影响生活质量。早期髋部缺血性坏死可通过带或不带自体骨移植的髓芯减压手术进行治疗。全髋关节置换术是患有顽固性疼痛且身体状况适合进行该手术的患者疾病晚期的主要治疗方法。镰状细胞病患者髋部病变的管理面临众多医学和外科挑战，对患者进行仔细的围手术期管理是必不可少的。尽管镰状细胞病患者发生医学和手术并发症的风险增加，但全髋关节置换术可为适当选择的患者提供显著的疼痛缓解和功能改善。
